SS-31 vs MOTS-c.

SS-31, known generically as elamipretide and chemically as the tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine), is a synthetic, cell-permeable, mitochondria-targeting peptide of the "Szeto-Schiller" (SS) aromatic-cationic class, originally discovered by Hazel Szeto and Peter Schiller at Cornell during opioid-peptide work. It is the lead clinical candidate of this class and, as elamipretide HCl, received its first regulatory approval in 2025. It is best understood as a mitochondrial protective/bioenergetic agent rather than a growth-factor or "anabolic" peptide.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. It belongs to a small family of "mitochondrial-derived peptides" that appear to act as metabolic signaling molecules. It is an investigational research compound, not an approved drug, and is frequently grouped with longevity peptides where hype tends to outrun the evidence.

SS-31 carries an alternating aromatic-cationic motif giving it a net positive charge that drives selective, concentration-dependent accumulation (reported >1000-fold over cytosol) in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid unique to that membrane. By associating with cardiolipin it is thought to stabilize cristae architecture, protect the cardiolipin-cytochrome c interaction and electron-transport-chain organization, support membrane potential and ATP synthesis, and reduce mitochondrial reactive oxygen species. Unlike a classic free-radical scavenger, current biophysical work (e.g., studies of its effect on bilayer surface electrostatics) frames its primary action as modulation of mitochondrial membrane structure/electrostatics rather than simple antioxidant chemistry. These mechanisms are well characterized in cell and tissue models; the downstream clinical consequences in humans remain only partially established.

In preclinical models MOTS-c is described as a stress-responsive signaling peptide: it has been reported to activate the AMPK energy-sensing pathway and to influence folate and methionine (one-carbon) metabolism, and under metabolic stress it can translocate to the cell nucleus where it is proposed to help regulate adaptive, antioxidant gene expression. These mechanisms are largely characterized in cell and animal systems; how faithfully they translate to a clinical effect in people is not established.

The strongest human evidence is in Barth syndrome: based largely on the TAZPOWER program (an improvement in knee-extensor muscle strength taken as reasonably likely to predict clinical benefit), the FDA granted accelerated approval to elamipretide HCl (brand FORZINITY, Stealth BioTherapeutics) in September 2025 for Barth syndrome in patients weighing at least 30 kg, the first approved mitochondria-targeted peptide. In contrast, the larger Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (Karaa et al., Neurology 2023, ~218 participants) FAILED its co-primary endpoints (6-minute walk test and Total Fatigue Score), though post hoc analyses suggested possible benefit in a mitochondrial-DNA replisome/maintenance subgroup, motivating the follow-up NuPOWER trial. Trials in heart failure (PROGRESS-HF) and dry age-related macular degeneration (ReCLAIM) likewise missed their primary endpoints. Most other indications (kidney injury, aging, Barth cardiac and broader neurodegeneration) rest on preclinical/animal data, so the human evidence base is narrow and, outside Barth syndrome, largely negative or unproven.

The evidence base is predominantly preclinical. The foundational study (Lee et al., Cell Metabolism, 2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mice, and later work has linked it to exercise physiology and measured circulating levels in humans as a biomarker. However, there are no controlled human trials demonstrating that administering MOTS-c produces a meaningful clinical benefit. The gap between the animal/mechanistic data and proven human outcomes is large and should not be glossed over.

Across clinical trials the most commonly reported adverse events have been injection-site reactions (pain, redness, swelling) consistent with subcutaneous administration, with milder reports of headache, dizziness, and nausea; published trial data generally did not show clinically significant changes in vital signs, routine labs, or ECG over extended dosing. However, long-term safety beyond the studied trial populations, and safety of non-pharmaceutical "research-use" material sold outside the approved product, are not established. Because the only rigorously studied, quality-controlled form is the FDA-approved prescription product, gray-market SS-31 carries additional unknowns around purity, sterility, and identity. This summary describes documented findings only and intentionally excludes any dosing or administration details.

Human safety is essentially uncharacterized. There are no published human toxicology, long-term, or drug-interaction data for administered MOTS-c. As an injectable compound sold research-use-only, the purity, identity, and sterility of non-pharmaceutical material are additional unknowns on top of the absent clinical safety package. It should be regarded as an experimental compound of unknown human risk.

As elamipretide HCl (FORZINITY), SS-31 received FDA accelerated approval in September 2025 for Barth syndrome, making it the first approved mitochondria-targeted peptide; accelerated approval means continued approval may depend on confirmatory benefit. For all other uses (e.g., heart failure, mitochondrial myopathy, ophthalmic and "anti-aging" applications) it remains investigational or unproven, and material marketed as "SS-31" for research is not an FDA-approved drug for those purposes.

MOTS-c is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational, research-use-only compound with no registered human therapeutic trials.